Spark Investment Management’s Aimmune Therapeutics AIMT Stock Holding History

Spark Investment Management’s Portfolio AIMT Stock Details AIMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-6,800	Closed	-$234K	–	68
2020 Q3	$234K	Buy	+6,800	New	+$145K	0.33%	32
2020 Q2	–	Sell	-18,200	Closed	-$262K	–	358
2020 Q1	$262K	Hold	18,200	–	–	0.14%	201
2019 Q4	$609K	Buy	+18,200	New	+$509K	0.07%	321
2018 Q4	–	Sell	-209,000	Closed	-$5.7M	–	862
2018 Q3	$5.7M	Sell	209,000 -23,300	-10%	-$659K	0.33%	93
2018 Q2	$6.25M	Buy	232,300 +43,000	+23%	+$1.32M	0.37%	80
2018 Q1	$6.03M	Buy	+189,300	New	+$6.66M	0.38%	72

Spark Investment Management's AIMT Position: Q4 2020 in Review

Spark Investment Management sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 6,800 shares — an estimated $234K sold.

Spark Investment Management first reported a position in AIMT in Q1 2018 and held it in 6 quarters. The position peaked at $6.25M in Q2 2018. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.

Spark Investment Management reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
Spark Investment Management sold 6,800 Aimmune Therapeutics shares in Q4 2020, an estimated $234K.
Spark Investment Management first reported a position in Aimmune Therapeutics in Q1 2018 and held it in 6 quarters.
Spark Investment Management's Aimmune Therapeutics position peaked at $6.25M in Q2 2018.
0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.

Based on Spark Investment Management's 13F filing for Q4 2020, filed 11 Feb 2021.